OVERVIEW

Continuity in Cancer Care®: Aligning Primary and Oncology Specialty Care to Improve Long-Term Management of Multiple Myeloma (MM) Patients is organized by Physicians' Education Resource, LLC (PER).

Release Date: October 31, 2019
Expiration Date: October 31, 2020

Accreditation:
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Activity Overview:
Multidisciplinary care is a crucial element of supporting patients throughout the continuum of care for multiple myeloma (MM) as new treatment options improve progression-free and overall survival. Multidisciplinary care teams need to work cohesively to optimize clinical outcomes in areas such as bone health, mobility, safety, sexual dysfunction, kidney disease management, social and psychological health, and pain management.

Understanding the possible implications of constantly emerging clinical data in MM, both in the newly diagnosed setting and the relapsed/refractory setting, is important to the appropriate management of patients with MM. It is crucial to effectively manage potential adverse events associated with therapy, including thromboembolic risk (elevated in patients with MM) and treatment-related cardiotoxicity. Strategies for managing other adverse events, such as peripheral neuropathy, gastrointestinal toxicity, pulmonary toxicity, cutaneous reactions, tumor lysis syndrome, and hepatotoxicity must also be considered during the treatment planning process.

To help you meet this challenge, this Continuity in Cancer Care® will feature case presentations given by prominent experts in the field to discuss strategies that support the continuity of care for patients with MM. The latest data in the management of treatment- and nontreatment-related toxicities with comorbid conditions will be discussed as well as the implications for clinical practice.

Learning Objectives:
Upon successful completion of this educational activity, you should be better prepared to:
• Determine disease- and treatment-related toxicities among patients with myeloma in the context of common underlying comorbidities among patients with these tumors.
• Explain clinical trial evidence that informs decision making to individualize management approaches based on patient comorbidities in myeloma treatment settings.
• Apply individualized care approaches based on trial evidence that optimizes outcomes and integrates patient risk for short and long-term treatment-related comorbidity.
• Identify methods to coordinate care between the medical oncologist and primary care practitioners to optimize outcomes and mitigate risk among patients with myeloma.